00:47 , Jun 29, 2019 |  BioCentury  |  Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
23:26 , Jun 21, 2019 |  BC Extra  |  Preclinical News

June 21 Preclinical Quick Takes: AnaptysBio targets PD-1 for immune disease; plus Forty Seven, Homology and moreBy BioCentury Staff

AnaptysBio agonizes PD-1 for inflammatory disease  AnaptysBio Inc. (NASDAQ:ANAB) presented what CEO Hamza Suria called “the first data from anyone on a PD-1 agonist mAb” at the 2019 Federation of Clinical Immunology Societies (FOCiS) meeting...
20:47 , Jun 21, 2019 |  BC Extra  |  Clinical News

AnaptysBio shares sag as Sanofi-Regeneron trial stokes IL-33 doubts

A 12% dip in AnaptysBio's share price Friday suggests investors are concerned that a Phase II readout for a rival IL-33 inhibitor could indicate that the drug class may not provide a differentiated clinical benefit...
17:29 , Mar 8, 2019 |  BC Week In Review  |  Clinical News

Boehringer reports first data for IL-36R inhibitor in rare type of psoriasis

Boehringer said BI 655130 cleared symptoms of generalized pustular psoriasis within one week in a Phase I trial in seven patients experiencing an acute moderate-to-severe flare of the disease. BI 655130 is a mAb against...
01:03 , Jan 12, 2019 |  BioCentury  |  Finance

Warning: cash needed

  A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
16:05 , Nov 16, 2018 |  BC Week In Review  |  Clinical News

Tesaro combo leads to partial responses in NSCLC patients

Tesaro Inc. (NASDAQ:TSRO) reported data from the open-label Phase I AMBER trial showing that a combination of TSR-022 and TSR-042 led to four confirmed partial responses and 11 cases of stable disease among 31 evaluable...
01:14 , Oct 6, 2018 |  BioCentury  |  Finance

Large cap comeback

The biotech sector continued to be a stock pickers’ market through 3Q18 as there was a near even split between global biotech stocks that gained and lost value in the quarter. While 1H18 saw investors...
18:14 , Sep 28, 2018 |  BC Week In Review  |  Clinical News

AnaptysBio's asthma therapy improves eosinophil count and lung function in Phase IIa

AnaptysBio Inc. (NASDAQ:ANAB) reported interim data from a Phase IIa trial to treat severe eosinophilic asthma showing that etokimab (formerly ANB020) improved eosinophil count and lung function vs. placebo. A single 300 mg dose of...
18:13 , Sep 28, 2018 |  BC Week In Review  |  Financial News

AnaptysBio raises $208M following Phase IIa asthma readout

AnaptysBio Inc. (NASDAQ:ANAB) raised $207.8 million late Sept. 25 through the sale of 2.2 million shares at $94.46 in a follow-on underwritten by Credit Suisse, J.P. Morgan, Jefferies, Cantor, Guggenheim Securities and Wedbush PacGrow. The...